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Abstract: Orally disintegrating tablet (ODT) is a friendly dosage form that requires no access to water and serves as a 
solution to non-compliance. There are many co-processed adjuvants available in the market. However, there is no single 
product possesses all the ideal characteristics such as good compressibility, fast disintegration and good palatability for 
ODT application. The aim of this research was to produce a xylitol-starch base co-processed adjuvant which is suitable 
for ODT application. Two processing methods namely wet granulation and freeze drying were used to compare the 
characteristics of co-processed adjuvant comprising of xylitol, starch and crospovidone XL-10 mixed at various ratios. 
The co-processed excipients were compressed into ODT and physically characterized for powder flow, particle size, 
hardness, thickness, weight, friability, in-vitro disintegration time and in-situ disintegration time, lubricant sensitivity, 
dilution potential, Fourier transform infrared spectroscopy, scanning electronic microscopy and x-ray diffraction 
analysis. Formulation F6 was selected as the optimum formulation due to the fastest in-vitro (135.33±11.52 s) and in-situ 
disintegration time (88.67±13.56s) among all the formulations (p<0.05). Increase in starch component decreases 
disintegration time of ODT. The powder flow fell under the category of fair flow. Generally, it was observed that freeze 
drying method produced smaller particle size granules compared to wet granulation method. ODT produced from freeze 
drying method had shorter disintegration time compared to ODT from wet granulation batch. In conclusion, a novel co-
processed excipient comprised of xylitol, starch and crospovidone XL-10, produced using freeze drying method with fast 
disintegration time, good compressibility and palatability was developed and characterized. The co-processed excipient 
is suitable for ODT application. 
 




Orally disintegrating tablets (ODT) are also called as 
orodispersible tablet, mouth dissolving tablets, fast melt 
tablets, rapid dissolving tablets and quick dissolving 
(Hirani et al., 2009). It was first invented in 1970 to solve 
the issue of non-compliance. The ideal characteristics of 
an ODT are (a) fast disintegration time, (b) require no 
access to water, (c) good palatability and mouth feel, (d) 
robust and less friable, (e) stable, (f) simple 
manufacturing method such as direct compression, (g) 
consists of highly compressible excipients which allow 
high drug loading and (h) cost effective (Badgujar and 
Mundada, 2011).  
 
One of the simplest methods to produce ODT is through 
direct compression (Akram et al., 2011). However, there 
is no single pharmaceutical excipient possesses all the 
properties for direct compression. Co-processing is a 
technique to mix two or more excipients to produce an 
end product with functionality improvement and masking 
the undesirable properties of individual (Ambore et al., 
2014). A successful co-processing excipient has superior 
properties compared with physical mixtures of 
components or individual components in terms of flow 
properties, compressibility, dilution potential, fill weight 
uniformity, and reduced lubricant sensitivity (Nachaegari 
and Bansal, 2004). 
 
Although there is a number of commercial co-processed 
adjuvants in the market now, but not all are suitable for 
ODT application. Moreover, the available co-processed 
adjuvants have certain limitations. To summarize, the co-
processed adjuvant for ODT application must have good 
compressibility, achieving fast disintegration, good 
palatability and economical. 
 
Xylitol has excellent compressibility (Olinger and 
Karhunen, 1991). Moreover, it has intense sweet taste 
which will improve the palatability of ODT products 
(Lyn, 2012). Starch, apart from its low cost, is also an 
excellent disintegrant for which the disintegration 
mechanism depends majorly on swelling (Desai et al., 
2016). Crospovidone XL-10 is a super disintegrant which 
is effective at very small percentage to promote 
disintegration of ODT through wicking process (Desai et 
al., 2016). The aim of this research was to produce and 
characterize a co-processed adjuvant comprising of *Corresponding author: e-mail: anand@ucsiuniversity.edu.my 
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xylitol, starch and crospovidone XL-10. Two 
manufacturing methods namely wet granulation and 
freeze drying were compared to produce the xylitol-starch 
base co-processed adjuvant.  
 
MATERIALS AND METHODS 
 
Materials 
Soluble starch was purchased from Systerm Chemicals 
(Malaysia). Xylitol was obtained from Sigma Aldrich 
Chemical Co. (USA). Polyplasdone XL-10 was bought 
from ISP Technologies INC (USA). Microcrystalline 
cellulose was obtained from FMC Corporation (USA). 
Magnesium stearate was purchased from Peter Grevan 
(Holland). Paracetamol powder was purchased from Zulat 
Pharmacy Sdn Bhd (Malaysia). Tablettose was a free gift 
from Meggle Group (Germany).  
 
Development or co-processed adjuvant 
The co-processed adjuvant was consisted of three 
components which were xylitol, starch and crospovidone 
XL-10. Two processing methods were used to produce 
the co-processed adjuvant namely freeze drying and wet 
granulation. The formulations are presented in table 1. 
 
Freeze drying 
The three components at various compositions were 
weighed. Xylitol was dissolved in 200g of distilled water 
in a beaker. Starch and crospovidone XL-10 were 
dispersed in 200g of distilled water in another beaker. The 
two portions were mixed and the final weight of the 
mixture was adjusted to 800g. The mixture was 
homogenized using a homogenizer for 15 minutes. The 
homogenized mixture was transferred to a freezer at -
20˚C for freezing. The frozen sample was dried in a 
freeze dryer (Alpha 1-4 LD Plus) to freeze dry under 
vacuum suction for 24 hrs at -55°C. The dried granules 
were sieved through 1 mm mesh and stored for further 
evaluation (Dey et al., 2010). Co-processed adjuvant of 
200g per batch was produced.  
 
Wet granulation 
The three components at various compositions were 
weighed. Xylitol was dissolved in distilled water (20% 
w/w) as granulating fluid. Crospovidone XL-10 and 
starch were mixed using geometric dilution method. 
Granulating fluid was added to the mixture and mixed for 
15 minutes. The wet granules were transferred and dried 
in a Memmert UNB 500 oven (Germany) at 60°C for 3 
hours. The dried granules were sieved through a 1mm 
mesh and stored for further evaluation.  
 
Powder characterization 
Angle of repose 
Cone forming method with fixed base was applied to 
determine the angle of repose. Powder sample or granule, 
devoid of any aggregation, was poured from a fixed 
height of about 10 cm to a fixed base with diameter of 2.4 
cm, through a funnel supported by stand to form a 
symmetrical cone of powder mass. The hypotenuse of the 
powder mass (h) was measured in triplicate to calculate 
the angle of repose. 
 
Particle size determination 
A stack of sieves with diameters from 0.1-1.0 mm was 
arranged in descending order. The sample was placed on 
the top sieve and the entire system was agitated at a speed 
of 50 amplitudes for 15min. The granules remained on 
each sieve were collected at the end of the test and 
weighed using a Metler Toledo B-204-S analytical 
balance (USA).  
 
The samples retained on each sieve was collected, 





Where Wsieve is the weight of aggregates retained on a 
sieve and Wtotal is the total weight of the powder. 
 
The average particle size was calculated using the 




Where n is the weight retained (in gram), d is the aperture 
size (in µm). 
 
Compression of co-processed adjuvant and physical 
characterization  
The co-processed adjuvant was weighed and compressed 
using a STC ZP17 (Y112M-6B7) rotary tableting press 
(China) fitted with round, concave faced, 1 cm diameter 
punches and die assembly. The weight of each tablet was 
400 mg.  
 
Physical characterization of co-processed adjuvant 
Evaluation of hardness 
The hardness was determined using a Tab-Machines T-
MNT-20 hardness tester (India). Ten tablets were used 




The diameter and thickness of the tablets were determined 
with a Mitaka vernier calliper (Japan) as well as their 
hardness using hardness tester as mentioned above. Their 
radial tensile strengths was evaluated using the formula 
below: 
 
   
 
Where T is the radial tensile strength, F is the hardness of 
the tablet and d and t are the diameter and thickness 
respectively. Ten tablets were used in the study (n=10). 
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F1 F2 F3 F4 F5 F6 
Xylitol 5 4 3 5 4 3 
Starch 4 5 6 4 5 6 
CPV XL-10 1 1 1 1 1 1 
Manufacturing method WG WG WG FD FD FD 
WG = Wet granulation, FD = Freeze drying 
 





F1 F2 F3 F4 F5 F6 
Angle of repose (˚)* 45.35± 2.27 44.41±2.34 37.74±3.20 45.32±0.69 40.08±1.36 39.14±1.74 
Ave particle size (µm)** 728.04 733.18 737.28 487.45 569.76 617.21 
*P = 0.04; **P = 0.01 
 

























































Friability (%)* 0.71 0.12 0.02 0.03 0.17 0.08 


























*Parameter using 10 tablets for evaluation; **Parameter using 6 tablets for evaluation 
 
Table 4: Lubricant sensitivity ratio values for different concentration of magnesium stearate 
 
Lubricant sensitivity ratio Percentage of magnesium stearate used 
(%) Co-processed adjuvant F6 Starch Xylitol 
0.25% 20.83 25.31 45.00 
0.5% 41.96 46.30 46.67 
1% 58.93 66.98 65.00 
2% 60.42 68.52 70.83 
 




F6 Tablettose ® 
Taste 3.00 ± 0.00 3.00 ± 0.00 
After taste 3.00 ± 0.00 3.00 ± 0.00 
Mouth feel 2.67 ± 052 1.83 ± 0.75 
 
 Mean ± SD, N=10 
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Evaluation of weight 
The weight was determined using a Metler Toledo B-204-
S analytical balance (USA). Ten tablets were selected at 
random, weighed individually and the average weight of 
the tablets was calculated from the total weight. The 
weight variation of individual tablet compared with the 
average weight should not exceed 5% (n=10).  
 
Fig. 1: The mean tensile strength against compression 
force curves of various combinations of co-processed 
adjuvant Formulation F6 and paracetamol (PCM). Mean ± 
SD, N=6 
 
Evaluation of thickness 
The thickness was evaluated using a Mitaka vernier 
calliper (Japan). Ten tablets were used and the thickness 
variation of individual tablet compared with the average 
thickness should not exceed 5% (n=10).  
 
Friability 
The friability was evaluated using a Guoming CS-2 
friabilitor (China). Ten tablets were weighed, put into the 
friabilator and ran for 4 minutes at 25 rpm (n=10). During 
each revolution, the tablets were subjected to fall from a 
height of 6 inches. After completion, tablets were cleaned 
to make them free from any adhered dust and reweighed. 
The test was acceptable under the pharmacopoeia limit of 
less than 1% weight loss 
  
In-vitro disintegration time 
The in-vitro disintegration time was determined using an 
Electro Lab ED-2L disintegration tester (India) with 
distilled water at 37˚C as disintegration medium. Six 
tablets of each formulation were used in the study (n = 6). 
The in-vitro disintegration time of ODT should not 
exceed 3 minutes.  
 
In-situ disintegration time test  
The in-situ disintegration time was determined using six 
human volunteers (n=6). The time of completely 
disintegration of ODT in mouth was determined as the in-
situ disintegration time using a stop watch to measure. 
The in-situ disintegration time of ODT should not exceed 
3 minutes. 
Selection of optimum formulation 
The optimum formulation was selected based on the 
shortest in-vitro disintegration time. The optimum 
formulation was carried forward for the remaining tests. 
 
Dilution capacity 
A poorly compressible drug (paracetamol) was chosen as 
model drug. The drug was mixed with co-processed 
adjuvant at four different ratios (1: 4; 2: 3: 3: 2; 4: 1). The 
controlled formulation was the co-processed adjuvant 
without mixing with drug (0% drug mixture). For every 
category, the mixture was sub-divided into 5 batches and 
compressed using five different compression forces. The 
tensile strength of the tablet was plotted against the 
compression force used (n=6). Area under curve was 
calculated using trapezoidal method. The sum of area 
under the curve (AUCsum) of each mixture was divided by 
the AUC of the “0% drug mixture” to obtain Minchom 
and Armstrong (MA's) working potential (Habib et al., 
1996). The equation is listed below.  
  
Dilution capacity index = M. A.’s working potential x 
AUCsum (0% drug mixture)  
 
The dilution capacity optimum formulation was compared 
with microcrystalline cellulose, which is a common 
excipient used as filler in tablet formulation.  
 
Lubricant sensitivity 
Co-processed adjuvant and each individual excipient were 
mixed with magnesium stearate at 4 different 
concentrations (0.25, 0.50, 1 and 2%). The mixture was 
compressed into tablet and hardness of the tablet was 
determined. Five replicates of each formulation was 
conducted (n=5). Lubricant sensitivity ratio was also 
calculated using the equation below (Almaya and Aburub, 
2008): 
 
Hardness of ablet without lubricant – 
Hardness of tablet with lubricant LSR % = 
Harness of table without lubricant 
×100% 
 
Physico-chemical study  
Fourier Transformed Infra Red (FTIR)  
IR spectra of starch, xylitol, crospovidone XL-10 as well 
as the optimum co-processed adjuvant formulation were 
recorded using the Thermo Fisher Scientific Nicolet™ iS5 
FTIR spectrophotometer (USA) in the range of 4000-500 
cm–1 using potassium bromide discs (Gangude et al., 
2013). 
 
Scanning electronic microscopy (SEM) 
The samples of optimum co-processed adjuvant 
formulation and all the single component were observed 
using the SEM technique to study the morphology of 
particles. SEM images were obtained using Zeiss Supra 
55VP scanning electron microscope (Germany). The 
samples were mounted on a metal stub with double-sided 
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adhesive tapes. The samples were sputtered with a thin 
layer of platinum to improve the electrical conductivity 
prior to imaging (Garg et al., 2015). 
 
X-Ray diffraction analysis 
X-ray diffraction (XRD) patterns was obtained using a 
Siemens D 5000 diffracto meter (Germany) for optimum 
co-processed adjuvant formulation and the single 
component. The X-ray source was Kα radiation from a 
copper target with graphite monochromater. The X-ray 
tube was operated at a potential of 40 Kv and a current of 
30 Ma. The range (2Ɵ) of scans was from 2˚-50˚. The 
data were collected at room temperature (26˚C) and 
scanned with a step size of 0.03° 2 and a dwell time of 
38 seconds each step (Patel and Bhavsar, 2009). 
 
Palatability study  
The palatability of the optimum co-processed adjuvant 
formulation was evaluated by human panel. Six human 
volunteers were invited to participate in the study to 
evaluate the taste, aftertaste and mouth feel of the test 
samples. The 3-points Likert scale was used for the 
evaluation (Liew and Peh, 2015). The optimum 





Statistical analysis was performed using Statistical 
Procedure for Social Science (SPSS) statistical software 
(version 16, SPSS Inc, US). The results obtained from the 
physical characterization were analysed statistically using 
one-way analysis of variance (ANOVA). When there was 
a statistically significant difference, post-hoc Tukey HSD 
test was performed. A statistically significant difference 
was considered at p<0.05. The palatability study results 
were analysed using Mann-Whitney test. A statistically 




Angle of repose and particle size 
The results of angle of repose and average particle size of 
co-processed adjuvant F1-F6 are presented in table 2. 
Formulation F1, F2, F4 and F5 were in the category of 
passable flow while formulation F3 and F6 were in the 
 
Fig. 2: SEM micrographs of (A) Xylitol ; (B) Crospovidone XL-10 ; (C) Starch and (D) Co-processed adjuvant 
formula F6 
 
Effect of processing methods on xylitol-starch base co-processed adjuvant for orally disintegrating tablet application 
Pak. J. Pharm. Sci., Vol.33, No.2, March 2020, pp.551-559 556 
category of fair flow. The flowability improved with the 
increase in starch amount in the formulation and the 
difference was statistically significant (p<0.05). The 
flowability improved following an ascending order: F1< 
F2< F3 and F4< F5< F6.  
 
Fig. 3: FTIR spectrum of (A) Formulation F6; (B) Starch; 
(C) Crospovidone XL-10 ; Xylitol 
 
Physical characterization of co-processed adjuvant 
The results of evaluation of hardness, thickness, tensile 
strength, weight, friability, in-vitro disintegration time 
and in-situ disintegration time are presented in table 3. 
There was no thickness and weight of individual tablet 
exceeds 5% of the average thickness and weight of the 
tablets measured. This shows that the co-processed 
adjuvant produced has consistency in contents.  
 
The hardness of the tablets produced per batch was fixed 
at 3 – 5kg to assess the disintegration efficiency of the 
formulations. It was noticed that the tablets disintegrated 
faster when the amount of starch present in the 
formulation increased. F3 (60% starch) has shorter 
disintegration time compared to F2 (50% starch) and F1 
(40% starch). The trend was similar for batches of tablets 
produced using freeze drying method. Furthermore, 
tablets produced using freeze drying method was found 
disintegrated faster compared to tablets produced using 
wet granulation method when the same composition 
formulations are compared and the difference was 
statistically significant (F6< F3; F5< F2; F4< F1). 
 
Freeze dried co-processed adjuvant produced tablet with 
lower thickness in general compared to co-processed 
adjuvant prepared by wet granulation method. This might 
be attributed to the lower particle size of freeze dried co-
processed adjuvant. Compression of the lower particle 




The tensile strength against compression force curves for 
various combinations of co-processed adjuvant 
Formulation F6 and PCM are shown in fig. 1. Dilution 
capacity index of F6 was 4630.45, whereas dilution 
capacity index of MCC was 2632.85. The finding showed 
that the co-processed adjuvant Formulation F6 could be 




The lubricant sensitivity ratio (LSR) is presented in Table 
4. Increase in percentage of magnesium stearate decreased 
the hardness of the tablets. However, it was noticed that 
decrease in hardness of tablets produced from individual 
component was more prominent compared to F6 tablet.  
 
SEM 
The results of SEM are presented in fig. 2. Starch particle 
can be seen as spherical particles with smooth surface. 
Xylitol particles appeared as irregular crystal. The co-
processed adjuvant appeared as an agglomerate of 
particles which was an effect of mixing in dispersion form 
followed by freeze drying. The three individual excipients 




FT-IR was used to check interaction between excipient 
(Patel and Patel, 2009). Starch, xylitol, crospovidone XL-
10, and co-processed adjuvants and F6 were subjected to 
IR studies and the results are presented in fig. 3. The IR 
spectra of co-processed adjuvants was compared with the 
IR spectra of individual excipients. Characteristic bands 
of starch were observed at 1637 cm–1 (–C=O), 2932 cm–1 
(–CH2-cycloalkane) and 3385 cm
–1 (–OH stretching). The 
spectra of xylitol showed the bands at 1637 cm–1 (–C=O), 
2943 cm–1 (–CH2-cycloalkane) and 3400 cm
–1 (–OH 
stretching). The spectra of crospovidone XL-10 showed 
the bands at 1654 cm–1 (–C=O) and 2940 cm–1 (–CH2-
cycloalkane). The IR spectrum of the co-processed 
adjuvants F6 showed the respective characteristic bands 
of starch, xylitol and XL-10, since no new bands were 
observed it suggests that no chemical interaction took 




The X-RD diffractograms of co-processed adjuvant 
Formulation F6 and the individual components are 
presented in fig. 4. Xylitol is crystalline in nature whereas 
starch and crospovidone XL-10 are amorphous in nature. 
The intensity of the peaks in co-processed adjuvant was 
reduced when compared to individual component. The 
results showed that co-processing have changed the solid-
state property of the individual components.  
 
Palatability study 
The results of palatability study are presented in Table 5. 
Optimum co-processed adjuvant formulation F6 and 
Tablettose® were compressed into ODT and tested for the 
palatability using human volunteer panel. Tablettose® was 
chosen as comparison because it is a common co-
Liew Kai Bin et al 
Pak. J. Pharm. Sci., Vol.33, No.2, March 2020, pp.551-559 557 
processed adjuvant used in tablet formulation. The results 
showed that both are neutral in taste and after taste (no 
bitterness). However, in terms of mouthfeel, co-processed 
adjuvant F6 scored higher than Tablettose® tablets. A 
better mouth feel signifies lesser grittiness. Co-processed 
adjuvant F6 contains xylitol, which will leave a soothing 
effect on the tongue when it dissolves. This gives an 
added advantage of the newly invented xylitol-starch base 




Angle of repose and particle size 
The flowability is an important parameter concerning 
uniform feed from bulk storage containers or hoppers into 
the feed mechanism of tabletting. Proper flow is always 
desired to allow uniform particle packing and a constant 
volume-to-mass ratio, which maintains tablet weight 
uniformity (Staniforth and Aulton, 2002) Moreover, 
powder with good flowability reduces the inter-batch 
variation hence enhances the reproducibility. Powder with 
good flowability produces products of more consistent 
physicochemical properties. Uneven powder flow can 
result in excess entrapped air within powders, which in 
some high-speed tabletting conditions may promote 
capping or lamination (Sandler et al., 2010). 
 
For particle size, it was observed that the average particle 
size increased with an increase in amount of starch in the 
formulation. The trend was the same for formulations 
produced using both methods. Moreover, it was also 
noticed that formulations produced using wet granulation 
had larger particle size compared to formulations 
produced using freeze drying method. As a result, 
 
Fig. 4: X-RD diffractogram (A) Formulation F6; (B) Starch ; (C) Crospovidone XL-10 ; (D) Xylitol 
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improvement in flowability can be correlated with the 
increase in average particle size.  
 
The flowability of powder is a multifunctional parameter 
which depends on particle size and size distribution, 
shape, particle interactions and moisture content (Jiang et 
al., 2009). Moreover, in a study conducted by Hart 
(2015), it was found that the strength of the produced 
tablet was dependent on the particle size of the powder. 
Powder of smaller sizes showed higher tensile strength 
than larger particles because of their large surface area 
available for bonding (Hart, 2015). Mullarney and Leyva 
(2009) investigated the possibility of predicting powder 
flowability based on the particle size distribution data. It 
was reported that powder with larger particle size 
possesses better flowability in general.  
 
Physical characterization 
The tablets produced from co-processed adjuvant 
disintegrates through three mechanisms: wicking of 
crospovidone that causes capillary effect and draws water 
into the tablet structure, swelling of starch and dissolution 
of xylitol. Starch swells when it comes in contact with 
water promoting disintegration (Herbert et al., 1989). It is 
noticed that formulation with higher starch content 
disintegrates faster due to the swelling effect of starch. 
 
Dilution potential and lubricant sensitivity 
Magnesium stearate is reported to adversely affect the 
binding properties of tablet excipients when used as a 
lubricant in tablet formulation (Mužíková and Eimerová, 
2011). A good co-processed adjuvant should have a lower 
lubricant sensitivity ratio. 
 
SEM 
Starch will swell and expand when it is dispersed in water 
(Zhou et al., 2007). The swelling property of starch 
enables the particle to expand and entangle with xylitol 




In conclusion, a co-processed adjuvant suitable for ODT 
application was formulated and characterized. The co-
processed adjuvant contains xylitol, starch and 
crospovidone XL-10 at a ratio of 3: 6: 1. Freeze drying is 
the preferred method. ODT produced from the co-
processed adjuvant has good mechanical strength and fast 
disintegration time of less than 3 minutes. The co-
processed adjuvant uses dissolution, swelling and wicking 
as the main disintegration mechanism respectively. The 
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